Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Lynparza
(Canada) [Available]Synonyms :
olaparib
Class :
Antineoplastic agents and PARP inhibitors
Brand Name :
Lynparza
(Canada) [Available]Synonyms :
olaparib
Class :
Antineoplastic agents and PARP inhibitors
Dosage forms & Strengths:Â
TabletÂ
100mgÂ
150mgÂ
Recurrent ovarian cancer
300 mg of the drug in the form of tablets is administered orally twice daily to patients with recurrent and advanced ovarian cancer
Continue the drug therapy until the disease reduces to unacceptable toxicity
Advanced ovarian cancer
Monotherapy
300 mg orally twice daily
Continue the treatment until unacceptable toxicity, disease progression, or completion of 2 years
After 2 years, if no radiologic evidence is seen, stop the treatment. If the disease persists, continue the treatment
Combination therapy
300 mg olaparib orally twice daily plus bevacizumab 15 mg/kg intravenously every 3 weeks for a total of 15 months
Continue the treatment until unacceptable toxicity, disease progression, or completion of 2 years
300 mg orally twice daily. Continue for a year or until unacceptable toxicity, disease recurrence, or whichever occurs first
300 mg orally twice daily. Continue for a year or until unacceptable toxicity, disease recurrence, or whichever occurs first
Indicated for Metastatic Castration-Resistant Prostate Cancer
300 mg orally twice daily. Continue for a year or until unacceptable toxicity, disease recurrence, or whichever occurs first
The safety and efficacy of olaparib are not found for pediatric dosingÂ
Refer to the adult dosingÂ
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 Inhibitors
olaparib: they may diminish the serum concentration of CYP3A4 Inducers
olaparib: they may diminish the serum concentration of CYP3A4 Inducers
olaparib: they may diminish the serum concentration of CYP3A4 Inducers
olaparib: they may diminish the serum concentration of CYP3A4 Inducers
olaparib: they may diminish the serum concentration of CYP3A4 Inducers
the effect of olaparib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib increases the effect of olaparib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of olaparib
when both drugs are combined, there may be an increase in adverse/toxic effects of bone marrow suppression and neutropenic effect
it may increase the adverse effects such as bone marrow suppression activity
CYP3A4 inducers decrease the concentration of olaparib in serum
Aminosalicylic Acid Derivatives
they enhance the effect of myelosuppression in myelosuppressive agents
it enhances the toxic effect of myelosuppressive agents
they increase the concentration of olaparib in serum
they enhance the effect of myelosuppression in the olaparib
they enhance the effect of myelosuppression in myelosuppressive agents
myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib
myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib
myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib
myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib
myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib
may have an increased myelosuppressive effect when combined with olaparib
may have an increased myelosuppressive effect when combined with olaparib
may have an increased myelosuppressive effect when combined with olaparib
may have an increased myelosuppressive effect when combined with olaparib
may have an increased myelosuppressive effect when combined with olaparib
olaparib: they may increase the myelosuppressive effect of myelosuppressive agents
By synergism effects, the toxicity of the other drug increases.
when both drugs are combined, there may be a decreased metabolism of vincristine  
myelosuppressive agents may enhance adverse myelosuppressive effects of Olaparib
myelosuppressive agents may enhance adverse myelosuppressive effects of Olaparib
myelosuppressive agents may enhance adverse myelosuppressive effects of olaparib
myelosuppressive agents may enhance adverse myelosuppressive effects of Olaparib
may enhance the risk of bone marrow suppression
may enhance the adverse effects such as bone marrow suppression
may enhance the risk of immunosuppression and bone marrow suppression
may increase myelosuppression and immunosuppression
when used in combination, both the drugs increase the levels of one another through synergistic activity
may enhance and prolong the myelosuppression activity
may increase myelosuppression and immunosuppression
may increase the risk of bone marrow suppression
when both drugs are combined, there may be an increase in the risk of the myelosuppressive effect of olaparib 
agents responsible for myelosuppression increase the myelosuppressive efficacy of Olaparib
myelosuppressive agents increase the effect of myelosuppression of olaparib
may enhance the adverse effects such as bone marrow suppression
may increase the toxic effect of myelosuppressive effect
may increase the myelosuppressive effect of myelosuppressive agents
may increase the myelosuppressive effect of Myelosuppressive Agents
may increase the immunosuppressive effect of Immunosuppressants
Actions and Spectrum:Â
Actions:Â
olaparib is primarily used to treat certain types of cancers, such as ovarian and breast cancers, that have mutations in the BRCA1 or BRCA2 genes. These mutations impair the cells’ ability to repair DNA damage, making them more susceptible to the effects of olaparib.Â
Spectrum:Â
Frequency defined:Â Â
>10%Â
Decreased hemoglobin Â
Increased mean corpuscular volume Â
Nausea Â
Decrease leukocytes Â
FatigueÂ
Decreased lymphocytes Â
Decreased ANCÂ Â
Abdominal pain Â
Vomiting Â
Anemia Â
Diarrhea Â
Decreased platelets Â
Increased serum creatinine Â
Constipation Â
Upper respiratory tract infection Â
Dysgeusia Â
AnemiaÂ
Dizziness Â
Decreased appetite Â
Decreased hemoglobinÂ
Neutropenia Â
Dyspepsia Â
Dyspnea Â
Decreased lymphocytesÂ
Urinary tract infection Â
Thrombocytopenia Â
Stomatitis Â
1-10%Â
NeutropeniaÂ
FatigueÂ
LeukopeniaÂ
DiarrheaÂ
Abdominal painÂ
ThrombocytopeniaÂ
NauseaÂ
Minor:Â
Contraindication/Caution:Â
Pregnancy consideration: The drug is toxic and unsafe for pregnant women and the developing fetus. It may cause fetal death or lower birth weight.Â
Breastfeeding warnings: No data on the excretion of olaparib in breast milk is available. Due to the possibility of serious adverse effects, women are advised to breastfeed one month after the last dose of olaparib.Â
Pregnancy category:Â
Pharmacology:Â
olaparib is a pharmacological agent that belongs to a class of drugs called PARP inhibitors. PARP inhibitors work by inhibiting the activity of the PARP enzyme, which is involved in repairing damaged DNA. By inhibiting this enzyme, olaparib prevents cancer cells from repairing their DNA, leading to death. olaparib is primarily used to treat certain types of cancers, such as ovarian and breast cancers, that have mutations in the BRCA1 or BRCA2 genes.Â
Pharmacodynamics:Â
olaparib is a potent and selective PARP inhibitor. By inhibiting PARP, olaparib prevents cancer cells from repairing their DNA, leading to their death. olaparib has been shown to have anti-tumor activity in several types of cancers, particularly those with BRCA mutations. olaparib can sensitize cancer cells to chemotherapy by preventing them from repairing the DNA damage caused by chemotherapy.Â
Pharmacokinetics:Â
AbsorptionÂ
The bioavailability of tablet formulation is high Â
Peak plasma time is achieved in 1.5 hours (for tablet); 1 to 3 hours (for capsule)Â
The peak plasma concentration is 7.7 mcg/mL (tablet at steady-state)Â
The area under the curve is 49 mcg·hr/mL (tablet at steady state)Â
The steady state is achieved in 3-4 daysÂ
DistributionÂ
The bound protein is 82%Â
The volume of distribution is 158 L (for tablet); 167 L (for capsule)Â
MetabolismÂ
olaparib is metabolized primarily by CYP3A4/5Â
Elimination and ExcretionÂ
Half-life is 14.9 hours (for tablet); 11.9 hours (for capsule)Â
The plasma clearance rate is 7.4 L/hr (for tablet); 8.6 L/hr (for capsule)Â
The drug is excreted 44% in urine and 42% in fecesÂ
Administration:Â
olaparib is an oral medication that is taken by mouth. It is available in capsule and tablet form. The dose and administration schedule of olaparib may vary depending on the type of cancer being treated and other factors such as age, weight, and other medical conditions.Â
The usual dose of olaparib for ovarian cancer is 300 milligrams (mg) taken twice daily as capsules or tablets, usually with a 12-hour interval between doses. The capsules should be swallowed whole with water, and it can be taken with or without food. Patients should not crush, chew, or open the capsules. The tablets can be swallowed whole with water and taken with or without food.Â
For breast cancer, the usual dose of olaparib is 300 mg taken twice daily as tablets, usually with a 12-hour interval between doses. It is important to take olaparib as directed by the healthcare provider. Patients should not change the dose or the administration schedule of olaparib unless instructed by their healthcare provider.Â
Patient information leafletÂ
Generic Name: olaparib (Rx)Â
Pronounced: Oh-LAP-a-ribÂ
Why do we use olaparib?Â
olaparib is primarily used to treat certain cancers, particularly ovarian and breast cancers, with mutations in the BRCA1 or BRCA2 genes. These genes are involved in the repair of DNA, and mutations in these genes can increase the risk of developing certain cancers.Â
olaparib is a PARP inhibitor, which means that it inhibits the activity of the PARP enzyme that is involved in DNA repair. By inhibiting this enzyme, olaparib prevents cancer cells from repairing their DNA, leading to death.Â
olaparib has been shown to have anti-tumor activity in several types of cancers, particularly those with BRCA mutations. It is a maintenance therapy in patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. Olaparib can sensitize cancer cells to chemotherapy by preventing them from repairing the DNA damage caused by chemotherapy.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
